Market capitalization | $268.02m |
Enterprise Value | $168.21m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.51 |
P/S ratio (TTM) P/S ratio | 0.82 |
P/B ratio (TTM) P/B ratio | 1.43 |
Revenue growth (TTM) Revenue growth | -6.48% |
Revenue (TTM) Revenue | $326.65m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
4 Analysts have issued a Inogen, Inc. forecast:
4 Analysts have issued a Inogen, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 327 327 |
6%
6%
|
|
Gross Profit | 149 149 |
2%
2%
|
|
EBITDA | -35 -35 |
137%
137%
|
EBIT (Operating Income) EBIT | -55 -55 |
58%
58%
|
Net Profit | -92 -92 |
4%
4%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Inogen, Inc . engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products consists of Inogen One G4 system, Inogen One G3 system, Inogen One G2 system, and Inogen at Home. The company was founded by Alison Perry, Alison Bauerlein, Brenton Taylor and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.
Head office | United States |
CEO | Kevin Smith |
Employees | 834 |
Founded | 2001 |
Website | www.inogen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.